Core Insights - Crystal Tech Holdings (02228.HK) announced that its incubated company, ReviR, received approval from the National Medical Products Administration for the clinical trial of RTX-117, a small molecule pipeline for treating Charcot-Marie-Tooth disease (CMT), set to begin Phase I trials in Q1 2026 [1] - RTX-117 is the first Class 1 innovative drug targeting CMT in China and represents a significant milestone in the collaboration between ReviR and Crystal Tech, leveraging AI and robotic-assisted research for rare disease drug development [1][2] - The drug has also received IND approval and orphan drug designation from the FDA, allowing for priority review and extended market exclusivity in the U.S. [1] Company and Industry Summary - CMT is listed as the 17th rare disease in the first batch published by the National Health Commission in 2018, characterized by its progressive nature and high disability rate, with RTX-117's clinical approval marking a breakthrough in CMT treatment development in China [2] - The collaboration between ReviR and Crystal Tech utilizes AI and RNA technology, demonstrating the potential of AI-driven drug discovery to overcome economic bottlenecks in rare disease treatment [2][3] - Crystal Tech, as the first "AI + Robotics" stock in Hong Kong, has established a leading automated research infrastructure and intelligent drug development platform, gaining trust from 17 of the top 20 global pharmaceutical companies [3] - The company’s platform-based business model allows for the continuous incubation of innovative pipelines, providing partners with breakthrough innovations while sharing long-term value through revenue sharing [3]
晶泰控股赋能，国内首个AI+RNA小分子创新药获批临床